Published in Urol Oncol on June 12, 2009
Ultrasound of the prostate. Cancer Imaging (2010) 0.94
Imaging angiogenesis of genitourinary tumors. Nat Rev Urol (2010) 0.90
Factors influencing the degree of enhancement of prostate cancer on contrast-enhanced transrectal ultrasonography: correlation with biopsy and radical prostatectomy specimens. Br J Radiol (2012) 0.87
Multiparametric ultrasound in the detection of prostate cancer: a systematic review. World J Urol (2015) 0.84
Contrast-enhanced ultrasound as support for prostate brachytherapy treatment planning. J Contemp Brachytherapy (2012) 0.81
Ultrasonic Nanobubbles Carrying Anti-PSMA Nanobody: Construction and Application in Prostate Cancer-Targeted Imaging. PLoS One (2015) 0.79
Identifying Clinically Significant Prostate Cancers using 3-D In Vivo Acoustic Radiation Force Impulse Imaging with Whole-Mount Histology Validation. Ultrasound Med Biol (2016) 0.79
Parameters predicting postoperative unilateral disease in patients with unilateral prostate cancer in diagnostic biopsy: a rationale for selecting hemiablative focal therapy candidates. Can Urol Assoc J (2013) 0.79
The utility and limitations of contrast-enhanced ultrasound for the diagnosis and treatment of prostate cancer. Sensors (Basel) (2015) 0.78
Prostate cancer: a comparison of the diagnostic performance of transrectal ultrasound versus contrast enhanced transrectal ultrasound in different clinical characteristics. Int J Clin Exp Med (2015) 0.75
Radical prostatectomy specimens - a voice against focal therapy. Cent European J Urol (2014) 0.75
Recent advances in focal therapy of prostate and kidney cancer. F1000 Med Rep (2010) 0.75
Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer. Eur Radiol (2016) 0.75
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol (2013) 7.48
Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol (2010) 4.60
Urethral stricture: etiology, investigation and treatments. Dtsch Arztebl Int (2013) 3.57
Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol (2008) 3.37
An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest (2003) 3.19
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res (2006) 2.62
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol (2006) 2.51
Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol (2008) 2.43
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol (2008) 2.33
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31
Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30
Mid-term results for the retroluminar transobturator sling suspension for stress urinary incontinence after prostatectomy. BJU Int (2010) 2.26
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int (2007) 2.25
Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development (2006) 2.20
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol (2005) 2.13
The "all-seeing needle": initial results of an optical puncture system confirming access in percutaneous nephrolithotomy. Eur Urol (2011) 2.13
Repeat retrourethral transobturator sling in the management of recurrent postprostatectomy stress urinary incontinence after failed first male sling. Eur Urol (2010) 2.11
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol (2010) 2.11
Dual energy CT characterization of urinary calculi: initial in vitro and clinical experience. Invest Radiol (2008) 2.08
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks. Eur Urol (2009) 2.04
Urodynamic parameters after retrourethral transobturator male sling and their influence on outcome. Urology (2011) 2.04
Contemporary management of postprostatectomy incontinence. Eur Urol (2011) 2.01
Primitive neuroectodermal tumor: rare, highly aggressive differential diagnosis in urologic malignancies. Urology (2006) 1.94
Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol (2006) 1.86
Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int (2011) 1.85
Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res (2006) 1.84
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol (2006) 1.82
Plasma vaporisation of the prostate: initial clinical results. Eur Urol (2009) 1.80
A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol (2009) 1.78
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76
Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol (2007) 1.74
Complications of the AdVance transobturator male sling in the treatment of male stress urinary incontinence. Urology (2010) 1.70
Techniques and long-term results of surgical procedures for BPH. Eur Urol (2006) 1.65
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.65
Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study. Eur Urol (2011) 1.64
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Dual-energy CT in patients suspected of having renal masses: can virtual nonenhanced images replace true nonenhanced images? Radiology (2009) 1.63
Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol (2011) 1.62
Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol (2006) 1.61
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61
Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol (2006) 1.60
Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol (2011) 1.59
Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy. Eur Urol (2006) 1.59
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol (2010) 1.57
External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol (2011) 1.56
18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol (2012) 1.54
Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.54
Optimizing vesicourethral anastomosis healing after robot-assisted laparoscopic radical prostatectomy: lessons learned from three techniques in 1900 patients. J Endourol (2010) 1.52
High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol (2005) 1.51
Risk factors for pelvic lymphoceles post-radical prostatectomy. Int J Urol (2011) 1.51
Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol (2006) 1.50
Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology (2008) 1.50
Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol (2011) 1.49
Results of the AdVance transobturator male sling after radical prostatectomy and adjuvant radiotherapy. Urology (2010) 1.49